Quantitative Measurement of Communication Ability in Children with Angelman Syndrome

Summary by Allyson Berent, DVM, DACVIM Individuals affected with Angelman syndrome (AS) are known to have limited functional speech and are typically able to communicate through gestures, sounds, minimal signs, and augmentative communication devices (AAC). The lack of functional speech in AS is thought to be associated with cognitive delays and oral motor dysfunction. Traditional […]

Towards Therapeutics – The FIRE Team Series, Part I

Edwin Weeber, Ph.D. is a Professor in the Department of Molecular Pharmacology and Physiology and the Chief Scientific Officer at the University of South Florida Health Byrd Alzheimer Institute. Dr. Weeber also serves on the Foundation for Angelman Syndrome Therapeutic’s (FAST) Scientific Advisory Board and the FAST Integrative Research Environment (FIRE) Initiative.   The FIRE […]

Collaborating for Clinical Trials

Stakeholders meet to develop Biomarkers and Outcome Measures for clinical trials in Angelman Syndrome We are thrilled to announce that the Angelman Syndrome community has reached one of the most significant advancements in the field of Angelman Syndrome (AS) to date: representatives from six pharmaceutical companies, scientists, clinicians, therapists, parents, private industry, the Foundation for […]

Ketone esters for the treatment of seizures in AS – clinical trial coming soon!

Medical foods as an effective approach to management of Angelman Syndrome The following is a recount of a presentation about using therapeutic ketones (KES) through oral supplementation to improve the symptoms of Angelman Syndrome, presented by Angela Poff, Mike McCandless,  Donna Herber from Disruptive Nutrition at the FAST Summit in Chicago in December 2015. This is […]

Thank You…

Did you know that the Angelman community is the driving force behind research into treatments and a cure for Angelman Syndrome?  Did you know that the Angelman community, single handedly, funded both the research on and the clinical trial for Minocycline as a Treatment for Angelman Syndrome?  Did you know that the Angelman community has […]

Lite the Night on FIRE, a benefit for FAST

Please join us for a unique fundraising event on Friday, Sept. 11th, 2015 at Boston Harbor Hotel from 7:00-11:30pm. Enjoy great food & drinks, dancing to the band Fusion, guest speakers, silent auction, and inspiring “Lite the Night” paddle raise. FAST is committed to raising at least $20 million to continue support of the FIRE […]

FAST-initiated Clinical Trial

I want to thank all those parents who applied for enrollment in the minocycline clinical trial. The clinical trial began on schedule April 16, 2012. We are now at a point where half of the patients have received the drug for eight weeks and are beginning to be seen for their follow up appointments. As […]

FAST Receives $250,000 Anonymous Donation – Ambitious Research Project Underway

In 2008, the Foundation for Angelman Syndrome Therapeutics (FAST) was formed and invigorated the community with our fresh energy, our aggressive approach to Angelman Syndrome (AS) research, and our concise mission to bring practical treatment into current medical practice as quickly as possible. In April 2012, FAST was thrilled to receive an anonymous donation of […]